MDL Isentris Platform Selected by LEO Pharma
News Dec 22, 2005
As the first open-standards-based, n-tier discovery informatics platform designed for life sciences researchers, Isentris is effectively integrating the data and workflow applications scientists use every day and promoting a self-service research environment to enhance decision making and improve R&D productivity.
"LEO Pharma is a global company committed to developing innovative and efficacious products and associated services," said Karsten Linneberg, head of section, R&D IT, department of spectroscopy 751, LEO Pharma.
"As such, we are continually seeking to improve the day-to-day efficiency and productivity of our R&D teams."
"By playing a central role in integrating data and workflow applications and fostering knowledge-driven decisions, Isentris will accelerate and streamline LEO Pharma's intensive R&D activities."
"The complete MDL Isentris platform offers research organizations a clear path to better decisions, shorter cycle times and a higher return on investment," said Lars Barfod, president & chief executive officer of Elsevier MDL.
"We are delighted that LEO Pharma has elected to migrate from MDL® ISIS to the full suite of next-generation MDL Isentris products."
"This is further confirmation that Isentris is being accepted as the integrated informatics platform of choice for life sciences R&D organizations."
The MDL Isentris platform includes the MDL® Base user interface, MDL® Draw chemical drawing and rendering software, MDL® Core Interface middle tier with Integrating Data Source and the MDL® Direct chemical data cartridges for molecules and reactions.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018